Atlanta-Based Wound Therapy Firm Raises $2.3M

ATLANTA — Biofisica, a company focused on wound care therapy, has closed on $2.3 million in new financing.

The firm has developed technology that combines a moist wound-care dressing and electrical stimulation. The product, called POSiEFECT, is designed to speed healing. It has been approved for sale in the United Kingdom and Canada.

Biofisica is seeking approval for its technology in the U.S.

Last August, Biofisica closed on $2 million in venture debt financing from Leader Ventures.

The new funding will be used for marketing in the U.K. and planning initiatives in the U.S., the company said.

"We are very pleased that our investors continue to show a tremendous vote of confidence for the progress that we're making with our business plan and the recognition that POSiFECT(R) serves a critical need in the wound care market," said Rafael Andino, founder of Biofisica, in a statement.

Unilever Technology Ventures, Novartis Venture Funds, the Advanced Technology Development Center Seed Capital Fund in Atlanta, and several individuals provided the funding.

"We believe that Biofisica's POSiFECT technology represents an innovative and effective approach to the treatment of chronic wounds," said Dion Madsen, managing director of Physic Ventures, the General Partner for Unilever Technology Ventures. "Chronic wounds are currently poorly treated and this technology approach represents a very convenient and cost effective therapy that has the potential to improve the lives of millions of chronic wound care patients."